Advances in Hemophilia Therapy: From Conventional Factor Replacement Therapy, Extended Half-Life (EHL) Products to Non-Factor and Gene-Based Therapies
Turkish Journal of Internal Medicine · 29.07.2026 · 8 · 121-136
DOI: 10.46310/tjim.1972839 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Internal Medicine, online erschienen am 29.07.2026. Verfasst von Arihant Senthil und 7 weiteren Autor:innen. Die Arbeit nennt 63 Literaturangaben.
Abstract (Originalsprache)
Objective
Hemophilia, a genetic bleeding disorder caused by deficiencies in clotting factors VIII, IX, or XI, has transitioned from a fatal disease to a chronic but manageable condition. Traditional management with plasma-derived and recombinant factor replacement improved survival and reduced bleeding but remains limited by frequent infusions, inhibitor development, and incomplete protection against joint damage.
Methods
This narrative review was based on a literature search of PubMed/MEDLINE and Google Scholar, focusing on recent clinical studies, guidelines, and landmark publications on hemophilia therapies.
Results
Recent therapeutic advances have transformed hemophilia management by reducing treatment burden, improving bleed prevention, and enhancing patient quality of life. Extended half-life factor concentrates have decreased infusion frequency, while non-factor therapies have expanded effective prophylaxis for patients with and without inhibitors through convenient subcutaneous administration. Gene therapy has demonstrated sustained endogenous factor expression with substantial reductions in bleeding episodes, offering the potential for long-term disease modification. Despite these advances, challenges related to treatment durability, immune responses, patient eligibility, accessibility, and cost continue to limit widespread implementation.
Conclusion
This narrative review outlines the evolution of hemophilia therapy from replacement strategies to innovative mechanism-based approaches, emphasizing clinical outcomes, emerging challenges, and the imperative to translate advances into equitable, sustainable care.
Zitieren
APA
Senthil, A., Paul, T., Singh, K., Kamble, M., Hong, J., Dhalani, M., Bansal, V., & Jain, R. (2026). Advances in Hemophilia Therapy: From Conventional Factor Replacement Therapy, Extended Half-Life (EHL) Products to Non-Factor and Gene-Based Therapies. Turkish Journal of Internal Medicine, 8, 121-136. https://doi.org/10.46310/tjim.1972839
Vancouver
Senthil A, Paul T, Singh K, Kamble M, Hong J, Dhalani M, et al. Advances in Hemophilia Therapy: From Conventional Factor Replacement Therapy, Extended Half-Life (EHL) Products to Non-Factor and Gene-Based Therapies. Turkish Journal of Internal Medicine. 2026;8:121-136. doi:10.46310/tjim.1972839
BibTeX
@article{Senthil2026,
author = {Senthil, Arihant and Paul, Tashvin and Singh, Karanbir and Kamble, Mahima and Hong, Jinpyo and Dhalani, Mayank and Bansal, Vasu and Jain, Rohit},
title = {Advances in Hemophilia Therapy: From Conventional Factor Replacement Therapy, Extended Half-Life (EHL) Products to Non-Factor and Gene-Based Therapies},
journal = {Turkish Journal of Internal Medicine},
year = {2026},
volume = {8},
pages = {121--136},
doi = {10.46310/tjim.1972839}
}
EUVIMED